Randomized double ‐blind trial of amifostine versus placebo for radiation‐induced xerostomia in patients with head and neck cancer

ConclusionThere was no clear evidence that pretreatment with amifostine made any difference to the incidence of grade ≥2 acute or late xerostomia. Other toxicity tended to bemore severe with amifostine. There was no effect on failure ‐free or overall survival. Acknowledging the low statistical power, these results do not support the use of IV amifostine pre‐radiotherapy in HNSCC.
Source: Australasian Radiology - Category: Radiology Authors: Tags: Radiation Oncology —Original Article Source Type: research